convalescent plasma-Stanford University-COVID-19

Convalescent plasma-Stanford University-COVID-19 refers to the high-titer COVID-19 convalescent plasma evaluated in the Phase 3 C3PO (Clinical Trial of COVID-19 Convalescent Plasma in Outpatients) study. This investigational biologic therapy, led by Stanford University in collaboration with the NIH-sponsored SIREN network, involved the intravenous administration of blood plasma derived from donors who had recovered from SARS-CoV-2 infection. The plasma contained high levels of neutralizing antibodies (titers of 1:160 or greater) intended to provide passive immunization to prevent disease progression in high-risk outpatients with mild COVID-19. The trial was launched in August 2020 but was halted in February 2021 after an interim analysis by the Data and Safety Monitoring Board (DSMB) concluded that the treatment was unlikely to demonstrate efficacy in the study population. Final results published in the New England Journal of Medicine in August 2021 confirmed that the therapy did not prevent disease progression compared to placebo.

Other names

COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmahigh-titer convalescent plasmaSARS-CoV-2 convalescent plasmaSARS-CoV2 convalescent plasmaSARS-CoV 2 convalescent plasma